nodes	percent_of_prediction	percent_of_DWPC	metapath
Irinotecan—CES2—Mycophenolate mofetil—psoriasis	0.161	0.2	CbGbCtD
Irinotecan—UGT1A9—Mycophenolic acid—psoriasis	0.0607	0.0755	CbGbCtD
Irinotecan—CES1—Mycophenolate mofetil—psoriasis	0.0559	0.0695	CbGbCtD
Irinotecan—UGT1A1—Mycophenolic acid—psoriasis	0.0496	0.0617	CbGbCtD
Irinotecan—UGT1A9—Mycophenolate mofetil—psoriasis	0.0339	0.0422	CbGbCtD
Irinotecan—UGT1A1—Mycophenolate mofetil—psoriasis	0.0277	0.0345	CbGbCtD
Irinotecan—ALB—Acitretin—psoriasis	0.0225	0.0279	CbGbCtD
Irinotecan—BCHE—Triamcinolone—psoriasis	0.0217	0.027	CbGbCtD
Irinotecan—CYP3A5—Beclomethasone—psoriasis	0.0212	0.0264	CbGbCtD
Irinotecan—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0192	0.0239	CbGbCtD
Irinotecan—ABCC1—Cyclosporine—psoriasis	0.0173	0.0215	CbGbCtD
Irinotecan—ABCC2—Mycophenolate mofetil—psoriasis	0.0169	0.021	CbGbCtD
Irinotecan—ABCG2—Mycophenolate mofetil—psoriasis	0.0153	0.019	CbGbCtD
Irinotecan—SLCO1B1—Cyclosporine—psoriasis	0.0146	0.0181	CbGbCtD
Irinotecan—ABCC2—Cyclosporine—psoriasis	0.0128	0.0159	CbGbCtD
Irinotecan—CYP2B6—Cholecalciferol—psoriasis	0.0124	0.0154	CbGbCtD
Irinotecan—ABCG2—Hydrocortisone—psoriasis	0.0122	0.0152	CbGbCtD
Irinotecan—ABCG2—Cyclosporine—psoriasis	0.0116	0.0144	CbGbCtD
Irinotecan—ALB—Mycophenolate mofetil—psoriasis	0.0105	0.0131	CbGbCtD
Irinotecan—ABCC1—Methotrexate—psoriasis	0.00914	0.0114	CbGbCtD
Irinotecan—CYP3A7—Hydrocortisone—psoriasis	0.00904	0.0112	CbGbCtD
Irinotecan—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.00904	0.0112	CbGbCtD
Irinotecan—CYP3A7—Cyclosporine—psoriasis	0.00854	0.0106	CbGbCtD
Irinotecan—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.00854	0.0106	CbGbCtD
Irinotecan—CYP3A5—Mycophenolate mofetil—psoriasis	0.00845	0.0105	CbGbCtD
Irinotecan—ABCC2—Dexamethasone—psoriasis	0.00842	0.0105	CbGbCtD
Irinotecan—ALB—Prednisone—psoriasis	0.00841	0.0105	CbGbCtD
Irinotecan—SLCO1B1—Methotrexate—psoriasis	0.0077	0.00958	CbGbCtD
Irinotecan—ABCG2—Dexamethasone—psoriasis	0.00761	0.00947	CbGbCtD
Irinotecan—CYP3A4—Calcitriol—psoriasis	0.00738	0.00918	CbGbCtD
Irinotecan—CYP3A5—Hydrocortisone—psoriasis	0.00678	0.00844	CbGbCtD
Irinotecan—ABCC2—Methotrexate—psoriasis	0.00677	0.00842	CbGbCtD
Irinotecan—CYP3A5—Cyclosporine—psoriasis	0.00641	0.00797	CbGbCtD
Irinotecan—ABCG2—Methotrexate—psoriasis	0.00612	0.00761	CbGbCtD
Irinotecan—CYP3A4—Methoxsalen—psoriasis	0.00574	0.00714	CbGbCtD
Irinotecan—CYP3A7—Dexamethasone—psoriasis	0.00562	0.00699	CbGbCtD
Irinotecan—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00562	0.00699	CbGbCtD
Irinotecan—ABCB1—Mycophenolate mofetil—psoriasis	0.0055	0.00684	CbGbCtD
Irinotecan—CYP2B6—Dexamethasone—psoriasis	0.00535	0.00666	CbGbCtD
Irinotecan—ABCB1—Betamethasone—psoriasis	0.00472	0.00587	CbGbCtD
Irinotecan—ABCB1—Prednisolone—psoriasis	0.00466	0.00579	CbGbCtD
Irinotecan—ABCB1—Hydrocortisone—psoriasis	0.00441	0.00549	CbGbCtD
Irinotecan—ABCB1—Prednisone—psoriasis	0.0044	0.00547	CbGbCtD
Irinotecan—CYP3A5—Dexamethasone—psoriasis	0.00422	0.00525	CbGbCtD
Irinotecan—ALB—Methotrexate—psoriasis	0.00422	0.00525	CbGbCtD
Irinotecan—ABCB1—Cyclosporine—psoriasis	0.00417	0.00518	CbGbCtD
Irinotecan—CYP3A4—Cholecalciferol—psoriasis	0.0038	0.00473	CbGbCtD
Irinotecan—CYP3A4—Mycophenolate mofetil—psoriasis	0.0033	0.0041	CbGbCtD
Irinotecan—CYP3A4—Triamcinolone—psoriasis	0.0033	0.0041	CbGbCtD
Irinotecan—CYP3A4—Betamethasone—psoriasis	0.00283	0.00352	CbGbCtD
Irinotecan—CYP3A4—Prednisolone—psoriasis	0.00279	0.00347	CbGbCtD
Irinotecan—ABCB1—Dexamethasone—psoriasis	0.00275	0.00341	CbGbCtD
Irinotecan—CYP3A4—Hydrocortisone—psoriasis	0.00264	0.00329	CbGbCtD
Irinotecan—CYP3A4—Prednisone—psoriasis	0.00263	0.00328	CbGbCtD
Irinotecan—CYP3A4—Cyclosporine—psoriasis	0.0025	0.00311	CbGbCtD
Irinotecan—ABCB1—Methotrexate—psoriasis	0.00221	0.00274	CbGbCtD
Irinotecan—CYP3A4—Dexamethasone—psoriasis	0.00164	0.00205	CbGbCtD
Irinotecan—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.00011	0.00477	CbGpPWpGaD
Irinotecan—ACHE—Melatonin metabolism and effects—NFKB1—psoriasis	0.00011	0.00477	CbGpPWpGaD
Irinotecan—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000109	0.00471	CbGpPWpGaD
Irinotecan—TOP1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	0.000107	0.00464	CbGpPWpGaD
Irinotecan—TOP1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	0.000103	0.00447	CbGpPWpGaD
Irinotecan—TOP1—Circadian rythm related genes—JUN—psoriasis	0.000103	0.00446	CbGpPWpGaD
Irinotecan—UGT1A1—NRF2 pathway—TGFA—psoriasis	0.000101	0.00437	CbGpPWpGaD
Irinotecan—UGT1A9—NRF2 pathway—TGFA—psoriasis	0.000101	0.00437	CbGpPWpGaD
Irinotecan—ABCC2—NRF2 pathway—TGFA—psoriasis	9.83e-05	0.00426	CbGpPWpGaD
Irinotecan—ACHE—ATF-2 transcription factor network—NOS2—psoriasis	9.76e-05	0.00423	CbGpPWpGaD
Irinotecan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	9.63e-05	0.00418	CbGpPWpGaD
Irinotecan—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	9.5e-05	0.00412	CbGpPWpGaD
Irinotecan—TOP1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	9.35e-05	0.00406	CbGpPWpGaD
Irinotecan—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	9.14e-05	0.00397	CbGpPWpGaD
Irinotecan—ALB—Lipoprotein metabolism—APOE—psoriasis	8.94e-05	0.00388	CbGpPWpGaD
Irinotecan—SLC22A3—SLC-mediated transmembrane transport—CP—psoriasis	8.91e-05	0.00387	CbGpPWpGaD
Irinotecan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.86e-05	0.00384	CbGpPWpGaD
Irinotecan—Hyperhidrosis—Hydrocortisone—psoriasis	8.79e-05	0.000508	CcSEcCtD
Irinotecan—Dyspepsia—Mycophenolate mofetil—psoriasis	8.78e-05	0.000508	CcSEcCtD
Irinotecan—Constipation—Cyclosporine—psoriasis	8.75e-05	0.000506	CcSEcCtD
Irinotecan—Pain—Cyclosporine—psoriasis	8.75e-05	0.000506	CcSEcCtD
Irinotecan—Renal failure—Methotrexate—psoriasis	8.71e-05	0.000504	CcSEcCtD
Irinotecan—Decreased appetite—Mycophenolate mofetil—psoriasis	8.67e-05	0.000502	CcSEcCtD
Irinotecan—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	8.67e-05	0.00376	CbGpPWpGaD
Irinotecan—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	8.67e-05	0.00376	CbGpPWpGaD
Irinotecan—Anorexia—Hydrocortisone—psoriasis	8.66e-05	0.000501	CcSEcCtD
Irinotecan—Diarrhoea—Mycophenolic acid—psoriasis	8.65e-05	0.000501	CcSEcCtD
Irinotecan—Stomatitis—Methotrexate—psoriasis	8.64e-05	0.0005	CcSEcCtD
Irinotecan—Angiopathy—Prednisone—psoriasis	8.64e-05	0.0005	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	8.61e-05	0.000498	CcSEcCtD
Irinotecan—Immune system disorder—Prednisone—psoriasis	8.6e-05	0.000498	CcSEcCtD
Irinotecan—Malaise—Betamethasone—psoriasis	8.58e-05	0.000497	CcSEcCtD
Irinotecan—Malaise—Dexamethasone—psoriasis	8.58e-05	0.000497	CcSEcCtD
Irinotecan—Oedema—Triamcinolone—psoriasis	8.56e-05	0.000495	CcSEcCtD
Irinotecan—Anaphylactic shock—Triamcinolone—psoriasis	8.56e-05	0.000495	CcSEcCtD
Irinotecan—Vertigo—Dexamethasone—psoriasis	8.55e-05	0.000495	CcSEcCtD
Irinotecan—Vertigo—Betamethasone—psoriasis	8.55e-05	0.000495	CcSEcCtD
Irinotecan—Syncope—Betamethasone—psoriasis	8.53e-05	0.000494	CcSEcCtD
Irinotecan—Syncope—Dexamethasone—psoriasis	8.53e-05	0.000494	CcSEcCtD
Irinotecan—Constipation—Mycophenolate mofetil—psoriasis	8.53e-05	0.000494	CcSEcCtD
Irinotecan—Pain—Mycophenolate mofetil—psoriasis	8.53e-05	0.000494	CcSEcCtD
Irinotecan—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	8.52e-05	0.0037	CbGpPWpGaD
Irinotecan—Arrhythmia—Prednisone—psoriasis	8.5e-05	0.000492	CcSEcCtD
Irinotecan—Infection—Triamcinolone—psoriasis	8.5e-05	0.000492	CcSEcCtD
Irinotecan—Sweating—Methotrexate—psoriasis	8.5e-05	0.000492	CcSEcCtD
Irinotecan—Hypotension—Hydrocortisone—psoriasis	8.49e-05	0.000491	CcSEcCtD
Irinotecan—Feeling abnormal—Cyclosporine—psoriasis	8.43e-05	0.000488	CcSEcCtD
Irinotecan—Shock—Triamcinolone—psoriasis	8.42e-05	0.000487	CcSEcCtD
Irinotecan—Insomnia—Prednisolone—psoriasis	8.42e-05	0.000487	CcSEcCtD
Irinotecan—Alopecia—Prednisone—psoriasis	8.41e-05	0.000487	CcSEcCtD
Irinotecan—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.37e-05	0.00363	CbGpPWpGaD
Irinotecan—Gastrointestinal pain—Cyclosporine—psoriasis	8.36e-05	0.000484	CcSEcCtD
Irinotecan—Loss of consciousness—Betamethasone—psoriasis	8.36e-05	0.000484	CcSEcCtD
Irinotecan—Loss of consciousness—Dexamethasone—psoriasis	8.36e-05	0.000484	CcSEcCtD
Irinotecan—Dizziness—Mycophenolic acid—psoriasis	8.36e-05	0.000484	CcSEcCtD
Irinotecan—Paraesthesia—Prednisolone—psoriasis	8.36e-05	0.000484	CcSEcCtD
Irinotecan—Hyperhidrosis—Triamcinolone—psoriasis	8.27e-05	0.000479	CcSEcCtD
Irinotecan—Feeling abnormal—Mycophenolate mofetil—psoriasis	8.22e-05	0.000476	CcSEcCtD
Irinotecan—Insomnia—Hydrocortisone—psoriasis	8.22e-05	0.000476	CcSEcCtD
Irinotecan—Hypertension—Betamethasone—psoriasis	8.22e-05	0.000475	CcSEcCtD
Irinotecan—Hypertension—Dexamethasone—psoriasis	8.22e-05	0.000475	CcSEcCtD
Irinotecan—Paraesthesia—Hydrocortisone—psoriasis	8.16e-05	0.000472	CcSEcCtD
Irinotecan—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	8.16e-05	0.000472	CcSEcCtD
Irinotecan—Abdominal pain—Cyclosporine—psoriasis	8.09e-05	0.000468	CcSEcCtD
Irinotecan—Body temperature increased—Cyclosporine—psoriasis	8.09e-05	0.000468	CcSEcCtD
Irinotecan—Vomiting—Mycophenolic acid—psoriasis	8.04e-05	0.000465	CcSEcCtD
Irinotecan—TOP1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	8.01e-05	0.00348	CbGpPWpGaD
Irinotecan—Discomfort—Betamethasone—psoriasis	8e-05	0.000463	CcSEcCtD
Irinotecan—Discomfort—Dexamethasone—psoriasis	8e-05	0.000463	CcSEcCtD
Irinotecan—Dyspepsia—Hydrocortisone—psoriasis	8e-05	0.000463	CcSEcCtD
Irinotecan—Haemoglobin—Methotrexate—psoriasis	8e-05	0.000463	CcSEcCtD
Irinotecan—Rash—Mycophenolic acid—psoriasis	7.97e-05	0.000461	CcSEcCtD
Irinotecan—Dermatitis—Mycophenolic acid—psoriasis	7.96e-05	0.000461	CcSEcCtD
Irinotecan—Pain—Prednisolone—psoriasis	7.96e-05	0.000461	CcSEcCtD
Irinotecan—Haemorrhage—Methotrexate—psoriasis	7.96e-05	0.00046	CcSEcCtD
Irinotecan—Headache—Mycophenolic acid—psoriasis	7.92e-05	0.000458	CcSEcCtD
Irinotecan—ACHE—Monoamine Transport—TNF—psoriasis	7.91e-05	0.00343	CbGpPWpGaD
Irinotecan—Decreased appetite—Hydrocortisone—psoriasis	7.9e-05	0.000457	CcSEcCtD
Irinotecan—Abdominal pain—Mycophenolate mofetil—psoriasis	7.89e-05	0.000456	CcSEcCtD
Irinotecan—Body temperature increased—Mycophenolate mofetil—psoriasis	7.89e-05	0.000456	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.85e-05	0.000454	CcSEcCtD
Irinotecan—Fatigue—Hydrocortisone—psoriasis	7.84e-05	0.000453	CcSEcCtD
Irinotecan—ACHE—Peptide hormone metabolism—LEP—psoriasis	7.82e-05	0.00339	CbGpPWpGaD
Irinotecan—Pain—Hydrocortisone—psoriasis	7.77e-05	0.00045	CcSEcCtD
Irinotecan—Anaphylactic shock—Dexamethasone—psoriasis	7.77e-05	0.000449	CcSEcCtD
Irinotecan—Oedema—Betamethasone—psoriasis	7.77e-05	0.000449	CcSEcCtD
Irinotecan—Anaphylactic shock—Betamethasone—psoriasis	7.77e-05	0.000449	CcSEcCtD
Irinotecan—Oedema—Dexamethasone—psoriasis	7.77e-05	0.000449	CcSEcCtD
Irinotecan—Insomnia—Triamcinolone—psoriasis	7.74e-05	0.000448	CcSEcCtD
Irinotecan—Infection—Betamethasone—psoriasis	7.72e-05	0.000446	CcSEcCtD
Irinotecan—Infection—Dexamethasone—psoriasis	7.72e-05	0.000446	CcSEcCtD
Irinotecan—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	7.71e-05	0.00334	CbGpPWpGaD
Irinotecan—Ill-defined disorder—Prednisone—psoriasis	7.69e-05	0.000445	CcSEcCtD
Irinotecan—Paraesthesia—Triamcinolone—psoriasis	7.69e-05	0.000445	CcSEcCtD
Irinotecan—Feeling abnormal—Prednisolone—psoriasis	7.67e-05	0.000444	CcSEcCtD
Irinotecan—Visual impairment—Methotrexate—psoriasis	7.67e-05	0.000444	CcSEcCtD
Irinotecan—Anaemia—Prednisone—psoriasis	7.66e-05	0.000443	CcSEcCtD
Irinotecan—Shock—Betamethasone—psoriasis	7.64e-05	0.000442	CcSEcCtD
Irinotecan—Shock—Dexamethasone—psoriasis	7.64e-05	0.000442	CcSEcCtD
Irinotecan—Dyspnoea—Triamcinolone—psoriasis	7.63e-05	0.000442	CcSEcCtD
Irinotecan—Nervous system disorder—Dexamethasone—psoriasis	7.62e-05	0.000441	CcSEcCtD
Irinotecan—Nervous system disorder—Betamethasone—psoriasis	7.62e-05	0.000441	CcSEcCtD
Irinotecan—Thrombocytopenia—Betamethasone—psoriasis	7.6e-05	0.00044	CcSEcCtD
Irinotecan—Thrombocytopenia—Dexamethasone—psoriasis	7.6e-05	0.00044	CcSEcCtD
Irinotecan—Hypersensitivity—Cyclosporine—psoriasis	7.54e-05	0.000436	CcSEcCtD
Irinotecan—Dyspepsia—Triamcinolone—psoriasis	7.53e-05	0.000436	CcSEcCtD
Irinotecan—Nausea—Mycophenolic acid—psoriasis	7.51e-05	0.000435	CcSEcCtD
Irinotecan—Hyperhidrosis—Betamethasone—psoriasis	7.51e-05	0.000434	CcSEcCtD
Irinotecan—Hyperhidrosis—Dexamethasone—psoriasis	7.51e-05	0.000434	CcSEcCtD
Irinotecan—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	7.5e-05	0.00325	CbGpPWpGaD
Irinotecan—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	7.5e-05	0.00325	CbGpPWpGaD
Irinotecan—Feeling abnormal—Hydrocortisone—psoriasis	7.49e-05	0.000433	CcSEcCtD
Irinotecan—ACHE—ATF-2 transcription factor network—IFNG—psoriasis	7.49e-05	0.00325	CbGpPWpGaD
Irinotecan—Malaise—Prednisone—psoriasis	7.47e-05	0.000432	CcSEcCtD
Irinotecan—Vertigo—Prednisone—psoriasis	7.45e-05	0.000431	CcSEcCtD
Irinotecan—Gastrointestinal pain—Hydrocortisone—psoriasis	7.43e-05	0.00043	CcSEcCtD
Irinotecan—Syncope—Prednisone—psoriasis	7.43e-05	0.00043	CcSEcCtD
Irinotecan—Anorexia—Betamethasone—psoriasis	7.4e-05	0.000428	CcSEcCtD
Irinotecan—Anorexia—Dexamethasone—psoriasis	7.4e-05	0.000428	CcSEcCtD
Irinotecan—Cardiac disorder—Methotrexate—psoriasis	7.38e-05	0.000427	CcSEcCtD
Irinotecan—Fatigue—Triamcinolone—psoriasis	7.38e-05	0.000427	CcSEcCtD
Irinotecan—Hypersensitivity—Mycophenolate mofetil—psoriasis	7.35e-05	0.000425	CcSEcCtD
Irinotecan—Asthenia—Cyclosporine—psoriasis	7.34e-05	0.000425	CcSEcCtD
Irinotecan—Pain—Triamcinolone—psoriasis	7.32e-05	0.000424	CcSEcCtD
Irinotecan—ALB—Hemostasis—SERPINB8—psoriasis	7.29e-05	0.00316	CbGpPWpGaD
Irinotecan—Loss of consciousness—Prednisone—psoriasis	7.28e-05	0.000421	CcSEcCtD
Irinotecan—Hypotension—Betamethasone—psoriasis	7.26e-05	0.00042	CcSEcCtD
Irinotecan—Hypotension—Dexamethasone—psoriasis	7.26e-05	0.00042	CcSEcCtD
Irinotecan—Angiopathy—Methotrexate—psoriasis	7.22e-05	0.000418	CcSEcCtD
Irinotecan—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	7.19e-05	0.00312	CbGpPWpGaD
Irinotecan—Immune system disorder—Methotrexate—psoriasis	7.19e-05	0.000416	CcSEcCtD
Irinotecan—Abdominal pain—Hydrocortisone—psoriasis	7.19e-05	0.000416	CcSEcCtD
Irinotecan—Body temperature increased—Hydrocortisone—psoriasis	7.19e-05	0.000416	CcSEcCtD
Irinotecan—Mediastinal disorder—Methotrexate—psoriasis	7.17e-05	0.000415	CcSEcCtD
Irinotecan—Asthenia—Mycophenolate mofetil—psoriasis	7.16e-05	0.000414	CcSEcCtD
Irinotecan—Hypertension—Prednisone—psoriasis	7.15e-05	0.000414	CcSEcCtD
Irinotecan—Chills—Methotrexate—psoriasis	7.14e-05	0.000413	CcSEcCtD
Irinotecan—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	7.08e-05	0.00307	CbGpPWpGaD
Irinotecan—TOP1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	7.06e-05	0.00306	CbGpPWpGaD
Irinotecan—ABCB1—Allograft Rejection—HLA-C—psoriasis	7.06e-05	0.00306	CbGpPWpGaD
Irinotecan—Feeling abnormal—Triamcinolone—psoriasis	7.05e-05	0.000408	CcSEcCtD
Irinotecan—Alopecia—Methotrexate—psoriasis	7.03e-05	0.000407	CcSEcCtD
Irinotecan—Insomnia—Betamethasone—psoriasis	7.02e-05	0.000406	CcSEcCtD
Irinotecan—Insomnia—Dexamethasone—psoriasis	7.02e-05	0.000406	CcSEcCtD
Irinotecan—ABCB1—Allograft Rejection—IL13—psoriasis	7.02e-05	0.00304	CbGpPWpGaD
Irinotecan—Diarrhoea—Cyclosporine—psoriasis	7e-05	0.000405	CcSEcCtD
Irinotecan—BCHE—Peptide hormone metabolism—LEP—psoriasis	6.98e-05	0.00303	CbGpPWpGaD
Irinotecan—Paraesthesia—Betamethasone—psoriasis	6.97e-05	0.000404	CcSEcCtD
Irinotecan—Paraesthesia—Dexamethasone—psoriasis	6.97e-05	0.000404	CcSEcCtD
Irinotecan—Discomfort—Prednisone—psoriasis	6.97e-05	0.000403	CcSEcCtD
Irinotecan—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	6.96e-05	0.00302	CbGpPWpGaD
Irinotecan—ACHE—ATF-2 transcription factor network—CXCL8—psoriasis	6.96e-05	0.00302	CbGpPWpGaD
Irinotecan—Hypersensitivity—Prednisolone—psoriasis	6.86e-05	0.000397	CcSEcCtD
Irinotecan—Dyspepsia—Betamethasone—psoriasis	6.84e-05	0.000396	CcSEcCtD
Irinotecan—Dyspepsia—Dexamethasone—psoriasis	6.84e-05	0.000396	CcSEcCtD
Irinotecan—Diarrhoea—Mycophenolate mofetil—psoriasis	6.83e-05	0.000395	CcSEcCtD
Irinotecan—TOP1—Circadian rythm related genes—TP53—psoriasis	6.78e-05	0.00294	CbGpPWpGaD
Irinotecan—Body temperature increased—Triamcinolone—psoriasis	6.77e-05	0.000392	CcSEcCtD
Irinotecan—Dizziness—Cyclosporine—psoriasis	6.76e-05	0.000391	CcSEcCtD
Irinotecan—Anaphylactic shock—Prednisone—psoriasis	6.76e-05	0.000391	CcSEcCtD
Irinotecan—Oedema—Prednisone—psoriasis	6.76e-05	0.000391	CcSEcCtD
Irinotecan—Decreased appetite—Betamethasone—psoriasis	6.75e-05	0.000391	CcSEcCtD
Irinotecan—Decreased appetite—Dexamethasone—psoriasis	6.75e-05	0.000391	CcSEcCtD
Irinotecan—Infection—Prednisone—psoriasis	6.72e-05	0.000389	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Dexamethasone—psoriasis	6.7e-05	0.000388	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Betamethasone—psoriasis	6.7e-05	0.000388	CcSEcCtD
Irinotecan—Back pain—Methotrexate—psoriasis	6.7e-05	0.000388	CcSEcCtD
Irinotecan—Hypersensitivity—Hydrocortisone—psoriasis	6.7e-05	0.000388	CcSEcCtD
Irinotecan—Fatigue—Dexamethasone—psoriasis	6.7e-05	0.000387	CcSEcCtD
Irinotecan—Fatigue—Betamethasone—psoriasis	6.7e-05	0.000387	CcSEcCtD
Irinotecan—Shock—Prednisone—psoriasis	6.65e-05	0.000385	CcSEcCtD
Irinotecan—Pain—Dexamethasone—psoriasis	6.64e-05	0.000384	CcSEcCtD
Irinotecan—Pain—Betamethasone—psoriasis	6.64e-05	0.000384	CcSEcCtD
Irinotecan—Nervous system disorder—Prednisone—psoriasis	6.63e-05	0.000384	CcSEcCtD
Irinotecan—Dizziness—Mycophenolate mofetil—psoriasis	6.6e-05	0.000382	CcSEcCtD
Irinotecan—Hyperhidrosis—Prednisone—psoriasis	6.54e-05	0.000378	CcSEcCtD
Irinotecan—Asthenia—Hydrocortisone—psoriasis	6.52e-05	0.000377	CcSEcCtD
Irinotecan—Vomiting—Cyclosporine—psoriasis	6.5e-05	0.000376	CcSEcCtD
Irinotecan—ACHE—ATF-2 transcription factor network—JUN—psoriasis	6.47e-05	0.00281	CbGpPWpGaD
Irinotecan—ABCB1—Allograft Rejection—IL17A—psoriasis	6.46e-05	0.0028	CbGpPWpGaD
Irinotecan—Rash—Cyclosporine—psoriasis	6.45e-05	0.000373	CcSEcCtD
Irinotecan—Anorexia—Prednisone—psoriasis	6.45e-05	0.000373	CcSEcCtD
Irinotecan—Dermatitis—Cyclosporine—psoriasis	6.44e-05	0.000373	CcSEcCtD
Irinotecan—Ill-defined disorder—Methotrexate—psoriasis	6.43e-05	0.000372	CcSEcCtD
Irinotecan—Headache—Cyclosporine—psoriasis	6.41e-05	0.000371	CcSEcCtD
Irinotecan—Anaemia—Methotrexate—psoriasis	6.4e-05	0.00037	CcSEcCtD
Irinotecan—Feeling abnormal—Dexamethasone—psoriasis	6.4e-05	0.00037	CcSEcCtD
Irinotecan—Feeling abnormal—Betamethasone—psoriasis	6.4e-05	0.00037	CcSEcCtD
Irinotecan—Gastrointestinal pain—Dexamethasone—psoriasis	6.35e-05	0.000367	CcSEcCtD
Irinotecan—Gastrointestinal pain—Betamethasone—psoriasis	6.35e-05	0.000367	CcSEcCtD
Irinotecan—Vomiting—Mycophenolate mofetil—psoriasis	6.34e-05	0.000367	CcSEcCtD
Irinotecan—Hypersensitivity—Triamcinolone—psoriasis	6.31e-05	0.000365	CcSEcCtD
Irinotecan—Rash—Mycophenolate mofetil—psoriasis	6.29e-05	0.000364	CcSEcCtD
Irinotecan—Dermatitis—Mycophenolate mofetil—psoriasis	6.29e-05	0.000364	CcSEcCtD
Irinotecan—Headache—Mycophenolate mofetil—psoriasis	6.25e-05	0.000362	CcSEcCtD
Irinotecan—Malaise—Methotrexate—psoriasis	6.25e-05	0.000361	CcSEcCtD
Irinotecan—Vertigo—Methotrexate—psoriasis	6.22e-05	0.00036	CcSEcCtD
Irinotecan—Diarrhoea—Hydrocortisone—psoriasis	6.22e-05	0.00036	CcSEcCtD
Irinotecan—TOP1—Circadian rythm related genes—IL6—psoriasis	6.21e-05	0.00269	CbGpPWpGaD
Irinotecan—Leukopenia—Methotrexate—psoriasis	6.2e-05	0.000359	CcSEcCtD
Irinotecan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.17e-05	0.00268	CbGpPWpGaD
Irinotecan—Dizziness—Prednisolone—psoriasis	6.15e-05	0.000356	CcSEcCtD
Irinotecan—Asthenia—Triamcinolone—psoriasis	6.14e-05	0.000355	CcSEcCtD
Irinotecan—Abdominal pain—Dexamethasone—psoriasis	6.14e-05	0.000355	CcSEcCtD
Irinotecan—Abdominal pain—Betamethasone—psoriasis	6.14e-05	0.000355	CcSEcCtD
Irinotecan—Body temperature increased—Betamethasone—psoriasis	6.14e-05	0.000355	CcSEcCtD
Irinotecan—Body temperature increased—Dexamethasone—psoriasis	6.14e-05	0.000355	CcSEcCtD
Irinotecan—ALB—Folate Metabolism—CAT—psoriasis	6.12e-05	0.00266	CbGpPWpGaD
Irinotecan—Insomnia—Prednisone—psoriasis	6.12e-05	0.000354	CcSEcCtD
Irinotecan—SLCO1B1—SLC-mediated transmembrane transport—CP—psoriasis	6.1e-05	0.00265	CbGpPWpGaD
Irinotecan—Nausea—Cyclosporine—psoriasis	6.08e-05	0.000352	CcSEcCtD
Irinotecan—Paraesthesia—Prednisone—psoriasis	6.07e-05	0.000351	CcSEcCtD
Irinotecan—Cough—Methotrexate—psoriasis	6.04e-05	0.00035	CcSEcCtD
Irinotecan—Dizziness—Hydrocortisone—psoriasis	6.01e-05	0.000348	CcSEcCtD
Irinotecan—ABCB1—Allograft Rejection—IL12B—psoriasis	6e-05	0.0026	CbGpPWpGaD
Irinotecan—ALB—Vitamin B12 Metabolism—CRP—psoriasis	5.98e-05	0.00259	CbGpPWpGaD
Irinotecan—Dyspepsia—Prednisone—psoriasis	5.95e-05	0.000344	CcSEcCtD
Irinotecan—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	5.94e-05	0.00258	CbGpPWpGaD
Irinotecan—Nausea—Mycophenolate mofetil—psoriasis	5.93e-05	0.000343	CcSEcCtD
Irinotecan—Decreased appetite—Prednisone—psoriasis	5.88e-05	0.00034	CcSEcCtD
Irinotecan—Rash—Prednisolone—psoriasis	5.87e-05	0.00034	CcSEcCtD
Irinotecan—Dermatitis—Prednisolone—psoriasis	5.86e-05	0.000339	CcSEcCtD
Irinotecan—ABCB1—Allograft Rejection—HLA-E—psoriasis	5.86e-05	0.00254	CbGpPWpGaD
Irinotecan—ALB—Vitamin B12 Metabolism—APOE—psoriasis	5.85e-05	0.00254	CbGpPWpGaD
Irinotecan—Fatigue—Prednisone—psoriasis	5.83e-05	0.000337	CcSEcCtD
Irinotecan—Headache—Prednisolone—psoriasis	5.83e-05	0.000337	CcSEcCtD
Irinotecan—Discomfort—Methotrexate—psoriasis	5.83e-05	0.000337	CcSEcCtD
Irinotecan—Constipation—Prednisone—psoriasis	5.78e-05	0.000335	CcSEcCtD
Irinotecan—Vomiting—Hydrocortisone—psoriasis	5.78e-05	0.000334	CcSEcCtD
Irinotecan—Rash—Hydrocortisone—psoriasis	5.73e-05	0.000332	CcSEcCtD
Irinotecan—Dermatitis—Hydrocortisone—psoriasis	5.73e-05	0.000331	CcSEcCtD
Irinotecan—Confusional state—Methotrexate—psoriasis	5.7e-05	0.00033	CcSEcCtD
Irinotecan—Headache—Hydrocortisone—psoriasis	5.69e-05	0.000329	CcSEcCtD
Irinotecan—Dizziness—Triamcinolone—psoriasis	5.66e-05	0.000327	CcSEcCtD
Irinotecan—Anaphylactic shock—Methotrexate—psoriasis	5.65e-05	0.000327	CcSEcCtD
Irinotecan—ALB—Folate Metabolism—IL4—psoriasis	5.63e-05	0.00244	CbGpPWpGaD
Irinotecan—Infection—Methotrexate—psoriasis	5.62e-05	0.000325	CcSEcCtD
Irinotecan—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	5.61e-05	0.00243	CbGpPWpGaD
Irinotecan—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	5.61e-05	0.00243	CbGpPWpGaD
Irinotecan—Feeling abnormal—Prednisone—psoriasis	5.57e-05	0.000322	CcSEcCtD
Irinotecan—Asthenia—Dexamethasone—psoriasis	5.57e-05	0.000322	CcSEcCtD
Irinotecan—Asthenia—Betamethasone—psoriasis	5.57e-05	0.000322	CcSEcCtD
Irinotecan—Nervous system disorder—Methotrexate—psoriasis	5.54e-05	0.000321	CcSEcCtD
Irinotecan—Thrombocytopenia—Methotrexate—psoriasis	5.53e-05	0.00032	CcSEcCtD
Irinotecan—Gastrointestinal pain—Prednisone—psoriasis	5.53e-05	0.00032	CcSEcCtD
Irinotecan—Nausea—Prednisolone—psoriasis	5.53e-05	0.00032	CcSEcCtD
Irinotecan—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	5.49e-05	0.00238	CbGpPWpGaD
Irinotecan—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	5.48e-05	0.00237	CbGpPWpGaD
Irinotecan—Hyperhidrosis—Methotrexate—psoriasis	5.46e-05	0.000316	CcSEcCtD
Irinotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	5.46e-05	0.00237	CbGpPWpGaD
Irinotecan—Vomiting—Triamcinolone—psoriasis	5.44e-05	0.000315	CcSEcCtD
Irinotecan—Nausea—Hydrocortisone—psoriasis	5.4e-05	0.000312	CcSEcCtD
Irinotecan—Rash—Triamcinolone—psoriasis	5.4e-05	0.000312	CcSEcCtD
Irinotecan—Dermatitis—Triamcinolone—psoriasis	5.39e-05	0.000312	CcSEcCtD
Irinotecan—Anorexia—Methotrexate—psoriasis	5.39e-05	0.000312	CcSEcCtD
Irinotecan—Headache—Triamcinolone—psoriasis	5.36e-05	0.00031	CcSEcCtD
Irinotecan—Abdominal pain—Prednisone—psoriasis	5.35e-05	0.000309	CcSEcCtD
Irinotecan—Body temperature increased—Prednisone—psoriasis	5.35e-05	0.000309	CcSEcCtD
Irinotecan—Diarrhoea—Dexamethasone—psoriasis	5.31e-05	0.000307	CcSEcCtD
Irinotecan—Diarrhoea—Betamethasone—psoriasis	5.31e-05	0.000307	CcSEcCtD
Irinotecan—Hypotension—Methotrexate—psoriasis	5.28e-05	0.000306	CcSEcCtD
Irinotecan—UGT1A9—PPARA activates gene expression—PPARG—psoriasis	5.26e-05	0.00228	CbGpPWpGaD
Irinotecan—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	5.15e-05	0.00223	CbGpPWpGaD
Irinotecan—Dizziness—Dexamethasone—psoriasis	5.14e-05	0.000297	CcSEcCtD
Irinotecan—Dizziness—Betamethasone—psoriasis	5.14e-05	0.000297	CcSEcCtD
Irinotecan—CYP3A4—Biological oxidations—CYP2S1—psoriasis	5.12e-05	0.00222	CbGpPWpGaD
Irinotecan—Insomnia—Methotrexate—psoriasis	5.11e-05	0.000296	CcSEcCtD
Irinotecan—Nausea—Triamcinolone—psoriasis	5.08e-05	0.000294	CcSEcCtD
Irinotecan—Paraesthesia—Methotrexate—psoriasis	5.08e-05	0.000294	CcSEcCtD
Irinotecan—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	5.04e-05	0.00219	CbGpPWpGaD
Irinotecan—Dyspnoea—Methotrexate—psoriasis	5.04e-05	0.000292	CcSEcCtD
Irinotecan—Somnolence—Methotrexate—psoriasis	5.02e-05	0.000291	CcSEcCtD
Irinotecan—Hypersensitivity—Prednisone—psoriasis	4.98e-05	0.000288	CcSEcCtD
Irinotecan—Dyspepsia—Methotrexate—psoriasis	4.98e-05	0.000288	CcSEcCtD
Irinotecan—Vomiting—Dexamethasone—psoriasis	4.94e-05	0.000286	CcSEcCtD
Irinotecan—Vomiting—Betamethasone—psoriasis	4.94e-05	0.000286	CcSEcCtD
Irinotecan—Decreased appetite—Methotrexate—psoriasis	4.91e-05	0.000284	CcSEcCtD
Irinotecan—Rash—Betamethasone—psoriasis	4.9e-05	0.000283	CcSEcCtD
Irinotecan—Rash—Dexamethasone—psoriasis	4.9e-05	0.000283	CcSEcCtD
Irinotecan—Dermatitis—Betamethasone—psoriasis	4.89e-05	0.000283	CcSEcCtD
Irinotecan—Dermatitis—Dexamethasone—psoriasis	4.89e-05	0.000283	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Methotrexate—psoriasis	4.88e-05	0.000282	CcSEcCtD
Irinotecan—SLC22A3—Metabolism—NDUFA5—psoriasis	4.87e-05	0.00211	CbGpPWpGaD
Irinotecan—Fatigue—Methotrexate—psoriasis	4.87e-05	0.000282	CcSEcCtD
Irinotecan—ALB—Selenium Micronutrient Network—CAT—psoriasis	4.87e-05	0.00211	CbGpPWpGaD
Irinotecan—Headache—Dexamethasone—psoriasis	4.87e-05	0.000282	CcSEcCtD
Irinotecan—Headache—Betamethasone—psoriasis	4.87e-05	0.000282	CcSEcCtD
Irinotecan—ALB—Folate Metabolism—CRP—psoriasis	4.86e-05	0.00211	CbGpPWpGaD
Irinotecan—Asthenia—Prednisone—psoriasis	4.85e-05	0.000281	CcSEcCtD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	4.85e-05	0.0021	CbGpPWpGaD
Irinotecan—Pain—Methotrexate—psoriasis	4.83e-05	0.00028	CcSEcCtD
Irinotecan—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	4.76e-05	0.00207	CbGpPWpGaD
Irinotecan—Feeling abnormal—Methotrexate—psoriasis	4.66e-05	0.00027	CcSEcCtD
Irinotecan—Diarrhoea—Prednisone—psoriasis	4.63e-05	0.000268	CcSEcCtD
Irinotecan—Gastrointestinal pain—Methotrexate—psoriasis	4.62e-05	0.000267	CcSEcCtD
Irinotecan—Nausea—Dexamethasone—psoriasis	4.61e-05	0.000267	CcSEcCtD
Irinotecan—Nausea—Betamethasone—psoriasis	4.61e-05	0.000267	CcSEcCtD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	4.54e-05	0.00197	CbGpPWpGaD
Irinotecan—SLC22A3—Transmembrane transport of small molecules—CP—psoriasis	4.53e-05	0.00196	CbGpPWpGaD
Irinotecan—Dizziness—Prednisone—psoriasis	4.47e-05	0.000259	CcSEcCtD
Irinotecan—ALB—Folate Metabolism—ICAM1—psoriasis	4.47e-05	0.00194	CbGpPWpGaD
Irinotecan—Abdominal pain—Methotrexate—psoriasis	4.47e-05	0.000259	CcSEcCtD
Irinotecan—Body temperature increased—Methotrexate—psoriasis	4.47e-05	0.000259	CcSEcCtD
Irinotecan—CYP3A4—Tryptophan metabolism—CAT—psoriasis	4.41e-05	0.00191	CbGpPWpGaD
Irinotecan—ABCB1—Allograft Rejection—IL10—psoriasis	4.39e-05	0.0019	CbGpPWpGaD
Irinotecan—SLC22A3—Transmembrane transport of small molecules—CARM1—psoriasis	4.32e-05	0.00187	CbGpPWpGaD
Irinotecan—Vomiting—Prednisone—psoriasis	4.3e-05	0.000249	CcSEcCtD
Irinotecan—ABCB1—Allograft Rejection—IL4—psoriasis	4.27e-05	0.00185	CbGpPWpGaD
Irinotecan—Rash—Prednisone—psoriasis	4.26e-05	0.000247	CcSEcCtD
Irinotecan—Dermatitis—Prednisone—psoriasis	4.26e-05	0.000247	CcSEcCtD
Irinotecan—Headache—Prednisone—psoriasis	4.24e-05	0.000245	CcSEcCtD
Irinotecan—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	4.18e-05	0.00181	CbGpPWpGaD
Irinotecan—ABCB1—Allograft Rejection—HLA-B—psoriasis	4.17e-05	0.00181	CbGpPWpGaD
Irinotecan—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	4.17e-05	0.00181	CbGpPWpGaD
Irinotecan—Hypersensitivity—Methotrexate—psoriasis	4.16e-05	0.000241	CcSEcCtD
Irinotecan—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.16e-05	0.00181	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—CYP2S1—psoriasis	4.14e-05	0.0018	CbGpPWpGaD
Irinotecan—Asthenia—Methotrexate—psoriasis	4.06e-05	0.000235	CcSEcCtD
Irinotecan—Nausea—Prednisone—psoriasis	4.02e-05	0.000232	CcSEcCtD
Irinotecan—ACHE—ATF-2 transcription factor network—IL6—psoriasis	3.91e-05	0.0017	CbGpPWpGaD
Irinotecan—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	3.89e-05	0.00169	CbGpPWpGaD
Irinotecan—ABCB1—Allograft Rejection—HLA-A—psoriasis	3.87e-05	0.00168	CbGpPWpGaD
Irinotecan—Diarrhoea—Methotrexate—psoriasis	3.87e-05	0.000224	CcSEcCtD
Irinotecan—ALB—Selenium Micronutrient Network—CRP—psoriasis	3.86e-05	0.00168	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—NDUFA5—psoriasis	3.84e-05	0.00166	CbGpPWpGaD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.81e-05	0.00165	CbGpPWpGaD
Irinotecan—ACHE—Metabolism of proteins—REN—psoriasis	3.81e-05	0.00165	CbGpPWpGaD
Irinotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.8e-05	0.00165	CbGpPWpGaD
Irinotecan—Dizziness—Methotrexate—psoriasis	3.74e-05	0.000216	CcSEcCtD
Irinotecan—UGT1A1—Metabolism—NDUFA5—psoriasis	3.64e-05	0.00158	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—NDUFA5—psoriasis	3.64e-05	0.00158	CbGpPWpGaD
Irinotecan—Vomiting—Methotrexate—psoriasis	3.59e-05	0.000208	CcSEcCtD
Irinotecan—ACHE—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.58e-05	0.00155	CbGpPWpGaD
Irinotecan—Rash—Methotrexate—psoriasis	3.56e-05	0.000206	CcSEcCtD
Irinotecan—Dermatitis—Methotrexate—psoriasis	3.56e-05	0.000206	CcSEcCtD
Irinotecan—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	3.55e-05	0.00154	CbGpPWpGaD
Irinotecan—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	3.55e-05	0.00154	CbGpPWpGaD
Irinotecan—Headache—Methotrexate—psoriasis	3.54e-05	0.000205	CcSEcCtD
Irinotecan—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	3.53e-05	0.00153	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—NDUFA5—psoriasis	3.51e-05	0.00152	CbGpPWpGaD
Irinotecan—ALB—SLC-mediated transmembrane transport—CP—psoriasis	3.49e-05	0.00151	CbGpPWpGaD
Irinotecan—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	3.48e-05	0.00151	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—NDUFA5—psoriasis	3.42e-05	0.00148	CbGpPWpGaD
Irinotecan—ALB—Folate Metabolism—IFNG—psoriasis	3.4e-05	0.00148	CbGpPWpGaD
Irinotecan—BCHE—Metabolism of proteins—REN—psoriasis	3.4e-05	0.00147	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.39e-05	0.00147	CbGpPWpGaD
Irinotecan—Nausea—Methotrexate—psoriasis	3.36e-05	0.000194	CcSEcCtD
Irinotecan—SLCO1B1—Metabolism—NDUFA5—psoriasis	3.34e-05	0.00145	CbGpPWpGaD
Irinotecan—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	3.3e-05	0.00143	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.27e-05	0.00142	CbGpPWpGaD
Irinotecan—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	3.26e-05	0.00141	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—CYP2S1—psoriasis	3.26e-05	0.00141	CbGpPWpGaD
Irinotecan—BCHE—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.19e-05	0.00138	CbGpPWpGaD
Irinotecan—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	3.15e-05	0.00137	CbGpPWpGaD
Irinotecan—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	3.11e-05	0.00135	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.11e-05	0.00135	CbGpPWpGaD
Irinotecan—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	3.1e-05	0.00134	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—CYP2S1—psoriasis	3.09e-05	0.00134	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—CYP2S1—psoriasis	3.09e-05	0.00134	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—NDUFA5—psoriasis	3.09e-05	0.00134	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—NDUFA5—psoriasis	3.06e-05	0.00133	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—CYP2S1—psoriasis	2.98e-05	0.00129	CbGpPWpGaD
Irinotecan—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	2.96e-05	0.00128	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—CYP2S1—psoriasis	2.91e-05	0.00126	CbGpPWpGaD
Irinotecan—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	2.87e-05	0.00124	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—CYP2S1—psoriasis	2.84e-05	0.00123	CbGpPWpGaD
Irinotecan—ALB—Folate Metabolism—NFKB1—psoriasis	2.83e-05	0.00123	CbGpPWpGaD
Irinotecan—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	2.74e-05	0.00119	CbGpPWpGaD
Irinotecan—ALB—Vitamin B12 Metabolism—TNF—psoriasis	2.71e-05	0.00117	CbGpPWpGaD
Irinotecan—ALB—Selenium Micronutrient Network—IFNG—psoriasis	2.7e-05	0.00117	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—CYP2S1—psoriasis	2.63e-05	0.00114	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—CYP2S1—psoriasis	2.6e-05	0.00113	CbGpPWpGaD
Irinotecan—ABCB1—Allograft Rejection—IFNG—psoriasis	2.58e-05	0.00112	CbGpPWpGaD
Irinotecan—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	2.58e-05	0.00112	CbGpPWpGaD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.53e-05	0.0011	CbGpPWpGaD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.43e-05	0.00106	CbGpPWpGaD
Irinotecan—ABCB1—Allograft Rejection—CXCL8—psoriasis	2.4e-05	0.00104	CbGpPWpGaD
Irinotecan—ACHE—Metabolism of proteins—ACE—psoriasis	2.38e-05	0.00103	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—NDUFA5—psoriasis	2.26e-05	0.000982	CbGpPWpGaD
Irinotecan—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.25e-05	0.000976	CbGpPWpGaD
Irinotecan—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	2.25e-05	0.000975	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—NDUFA5—psoriasis	2.21e-05	0.00096	CbGpPWpGaD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.21e-05	0.000958	CbGpPWpGaD
Irinotecan—ALB—Platelet degranulation—VEGFA—psoriasis	2.2e-05	0.000955	CbGpPWpGaD
Irinotecan—ALB—Folate Metabolism—TNF—psoriasis	2.2e-05	0.000955	CbGpPWpGaD
Irinotecan—ALB—Vitamin B12 Metabolism—IL6—psoriasis	2.18e-05	0.000947	CbGpPWpGaD
Irinotecan—BCHE—Metabolism of proteins—ACE—psoriasis	2.12e-05	0.00092	CbGpPWpGaD
Irinotecan—ALB—Hemostasis—ITGAL—psoriasis	2.12e-05	0.000919	CbGpPWpGaD
Irinotecan—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	2.1e-05	0.00091	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—CARM1—psoriasis	2.02e-05	0.000878	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.98e-05	0.000857	CbGpPWpGaD
Irinotecan—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.95e-05	0.000845	CbGpPWpGaD
Irinotecan—ALB—Folate Metabolism—TP53—psoriasis	1.94e-05	0.000842	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—CYP2S1—psoriasis	1.92e-05	0.000835	CbGpPWpGaD
Irinotecan—ALB—Metabolism—NDUFA5—psoriasis	1.91e-05	0.000827	CbGpPWpGaD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.89e-05	0.000821	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—CYP2S1—psoriasis	1.88e-05	0.000816	CbGpPWpGaD
Irinotecan—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.78e-05	0.000771	CbGpPWpGaD
Irinotecan—ALB—Folate Metabolism—IL6—psoriasis	1.78e-05	0.00077	CbGpPWpGaD
Irinotecan—ALB—Transmembrane transport of small molecules—CP—psoriasis	1.77e-05	0.000768	CbGpPWpGaD
Irinotecan—ALB—Selenium Micronutrient Network—TNF—psoriasis	1.75e-05	0.000758	CbGpPWpGaD
Irinotecan—ACHE—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.71e-05	0.000741	CbGpPWpGaD
Irinotecan—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	1.69e-05	0.000733	CbGpPWpGaD
Irinotecan—ABCB1—Allograft Rejection—TNF—psoriasis	1.67e-05	0.000724	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—NDUFA5—psoriasis	1.67e-05	0.000724	CbGpPWpGaD
Irinotecan—ACHE—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.67e-05	0.000724	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.66e-05	0.00072	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.62e-05	0.000703	CbGpPWpGaD
Irinotecan—ALB—Metabolism—CYP2S1—psoriasis	1.62e-05	0.000703	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—CARM1—psoriasis	1.59e-05	0.000691	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.56e-05	0.000678	CbGpPWpGaD
Irinotecan—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.55e-05	0.000673	CbGpPWpGaD
Irinotecan—BCHE—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.52e-05	0.000661	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—CARM1—psoriasis	1.51e-05	0.000656	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—CARM1—psoriasis	1.51e-05	0.000656	CbGpPWpGaD
Irinotecan—ACHE—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.49e-05	0.000646	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.49e-05	0.000645	CbGpPWpGaD
Irinotecan—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.48e-05	0.000642	CbGpPWpGaD
Irinotecan—ACHE—Metabolism of proteins—LEP—psoriasis	1.48e-05	0.000641	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—CARM1—psoriasis	1.46e-05	0.000632	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—CARM1—psoriasis	1.42e-05	0.000616	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—CYP2S1—psoriasis	1.42e-05	0.000616	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.41e-05	0.000613	CbGpPWpGaD
Irinotecan—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.41e-05	0.000612	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—CARM1—psoriasis	1.39e-05	0.000601	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.36e-05	0.000591	CbGpPWpGaD
Irinotecan—BCHE—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.33e-05	0.000576	CbGpPWpGaD
Irinotecan—BCHE—Metabolism of proteins—LEP—psoriasis	1.32e-05	0.000572	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.29e-05	0.000562	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—CARM1—psoriasis	1.28e-05	0.000556	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—CARM1—psoriasis	1.27e-05	0.000551	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—CAT—psoriasis	1.24e-05	0.00054	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.1e-05	0.000477	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.06e-05	0.00046	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—NDUFA5—psoriasis	1.03e-05	0.000446	CbGpPWpGaD
Irinotecan—ACHE—Metabolism of proteins—CXCL8—psoriasis	9.82e-06	0.000426	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—CAT—psoriasis	9.8e-06	0.000425	CbGpPWpGaD
Irinotecan—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	9.77e-06	0.000424	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—APOE—psoriasis	9.67e-06	0.000419	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	9.62e-06	0.000417	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—CARM1—psoriasis	9.4e-06	0.000408	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—CAT—psoriasis	9.3e-06	0.000403	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—CAT—psoriasis	9.3e-06	0.000403	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—CARM1—psoriasis	9.19e-06	0.000399	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—CAT—psoriasis	8.96e-06	0.000389	CbGpPWpGaD
Irinotecan—ABCC1—Disease—HLA-A—psoriasis	8.91e-06	0.000386	CbGpPWpGaD
Irinotecan—BCHE—Metabolism of proteins—CXCL8—psoriasis	8.76e-06	0.00038	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—CYP2S1—psoriasis	8.75e-06	0.000379	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—CAT—psoriasis	8.74e-06	0.000379	CbGpPWpGaD
Irinotecan—ALB—Hemostasis—NOS2—psoriasis	8.69e-06	0.000377	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—CAT—psoriasis	8.52e-06	0.000369	CbGpPWpGaD
Irinotecan—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.49e-06	0.000368	CbGpPWpGaD
Irinotecan—SLC22A3—Metabolism—PPARG—psoriasis	8.42e-06	0.000365	CbGpPWpGaD
Irinotecan—ABCC1—Disease—APOE—psoriasis	8.32e-06	0.000361	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	8.24e-06	0.000357	CbGpPWpGaD
Irinotecan—ALB—Metabolism—CARM1—psoriasis	7.91e-06	0.000343	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—CAT—psoriasis	7.89e-06	0.000342	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—CAT—psoriasis	7.82e-06	0.000339	CbGpPWpGaD
Irinotecan—ABCC1—Disease—NOS2—psoriasis	7.75e-06	0.000336	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—APOE—psoriasis	7.61e-06	0.00033	CbGpPWpGaD
Irinotecan—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.4e-06	0.000321	CbGpPWpGaD
Irinotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	7.27e-06	0.000315	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—APOE—psoriasis	7.22e-06	0.000313	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—APOE—psoriasis	7.22e-06	0.000313	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—APOE—psoriasis	6.97e-06	0.000302	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—CARM1—psoriasis	6.93e-06	0.000301	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—APOE—psoriasis	6.79e-06	0.000295	CbGpPWpGaD
Irinotecan—ACHE—Metabolism—PPARG—psoriasis	6.63e-06	0.000288	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—APOE—psoriasis	6.62e-06	0.000287	CbGpPWpGaD
Irinotecan—ABCC1—Disease—TYK2—psoriasis	6.35e-06	0.000275	CbGpPWpGaD
Irinotecan—UGT1A1—Metabolism—PPARG—psoriasis	6.29e-06	0.000273	CbGpPWpGaD
Irinotecan—UGT1A9—Metabolism—PPARG—psoriasis	6.29e-06	0.000273	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—APOE—psoriasis	6.13e-06	0.000266	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—APOE—psoriasis	6.08e-06	0.000263	CbGpPWpGaD
Irinotecan—ABCC1—Metabolism—PPARG—psoriasis	6.07e-06	0.000263	CbGpPWpGaD
Irinotecan—BCHE—Metabolism—PPARG—psoriasis	5.92e-06	0.000257	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—CAT—psoriasis	5.78e-06	0.000251	CbGpPWpGaD
Irinotecan—SLCO1B1—Metabolism—PPARG—psoriasis	5.77e-06	0.00025	CbGpPWpGaD
Irinotecan—ABCC1—Disease—CD4—psoriasis	5.74e-06	0.000249	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—CAT—psoriasis	5.65e-06	0.000245	CbGpPWpGaD
Irinotecan—ABCG2—Metabolism—PPARG—psoriasis	5.34e-06	0.000232	CbGpPWpGaD
Irinotecan—CYP3A7—Metabolism—PPARG—psoriasis	5.29e-06	0.00023	CbGpPWpGaD
Irinotecan—ALB—Hemostasis—VEGFA—psoriasis	5.03e-06	0.000218	CbGpPWpGaD
Irinotecan—ALB—Metabolism—CAT—psoriasis	4.87e-06	0.000211	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—APOE—psoriasis	4.49e-06	0.000195	CbGpPWpGaD
Irinotecan—ABCC1—Disease—STAT3—psoriasis	4.44e-06	0.000193	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—APOE—psoriasis	4.39e-06	0.00019	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—CARM1—psoriasis	4.27e-06	0.000185	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—CAT—psoriasis	4.26e-06	0.000185	CbGpPWpGaD
Irinotecan—CYP2B6—Metabolism—PPARG—psoriasis	3.91e-06	0.00017	CbGpPWpGaD
Irinotecan—CYP3A5—Metabolism—PPARG—psoriasis	3.83e-06	0.000166	CbGpPWpGaD
Irinotecan—ALB—Hemostasis—TP53—psoriasis	3.8e-06	0.000165	CbGpPWpGaD
Irinotecan—ALB—Metabolism—APOE—psoriasis	3.78e-06	0.000164	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—APOE—psoriasis	3.31e-06	0.000144	CbGpPWpGaD
Irinotecan—ALB—Metabolism—PPARG—psoriasis	3.29e-06	0.000143	CbGpPWpGaD
Irinotecan—ABCC1—Disease—IL6—psoriasis	3.1e-06	0.000135	CbGpPWpGaD
Irinotecan—ABCB1—Metabolism—PPARG—psoriasis	2.89e-06	0.000125	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—CAT—psoriasis	2.63e-06	0.000114	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—APOE—psoriasis	2.04e-06	8.85e-05	CbGpPWpGaD
Irinotecan—CYP3A4—Metabolism—PPARG—psoriasis	1.78e-06	7.71e-05	CbGpPWpGaD
